Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21461067 | 0.93 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461142 | 0.87 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461119 | 0.86 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL31249015 | 0.86 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461160 | 0.84 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461004 | 0.83 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461005 | 0.78 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461025 | 0.78 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL20672201 | 0.78 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL21461000 | 0.78 | MAP3K5 (1.00) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4537902-A2 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3773577-B1 | TRICYCLIC ASK1 INHIBITORS | TERNS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3773577-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10919911-B2 | Tricyclic ASK1 inhibitors | Terns, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919911-B2 | Tricyclic ASK1 inhibitors | Terns, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190315767-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315767-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2019200267-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019200267-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919911-B2 | Tricyclic ASK1 inhibitors | MAP3K1, MAP3K8, MAP3K20 | MAP3K5 12/4885 |
| US-20190315767-A1 | TRICYCLIC ASK1 INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | MAP3K5 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.